How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a former Pfizer division. Headquartered in Canonsburg, Pennsylvania, Viatris focuses on providing access to a broad range of medicines, including branded, generic, and over-the-counter drugs, as well as complex biologics and biosimilars. The company operates across multiple therapeutic areas, including cardiovascular, infectious diseases, oncology, and central nervous system disorders.

Companies valued at over $10 billion are typically classified as “large-cap stocks,” and Viatris fits the label perfectly with its market cap exceeding this threshold. VTRS benefits from a diverse product portfolio, global distribution, strong generics and biosimilars presence, vertical integration, and cost optimization efforts, positioning it as a competitive player in the pharmaceutical industry.